Emerald Advisers LLC Has $24.07 Million Holdings in NeoGenomics, Inc. (NEO)

Share on StockTwits

Emerald Advisers LLC raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 14.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,908,795 shares of the medical research company’s stock after buying an additional 236,965 shares during the quarter. NeoGenomics comprises about 1.2% of Emerald Advisers LLC’s investment portfolio, making the stock its 27th biggest position. Emerald Advisers LLC owned about 2.04% of NeoGenomics worth $24,070,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in NEO. BlackRock Inc. boosted its holdings in shares of NeoGenomics by 4.7% during the second quarter. BlackRock Inc. now owns 4,149,329 shares of the medical research company’s stock worth $54,397,000 after purchasing an additional 184,386 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of NeoGenomics by 28.2% during the second quarter. Dimensional Fund Advisors LP now owns 752,853 shares of the medical research company’s stock worth $9,870,000 after purchasing an additional 165,451 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of NeoGenomics during the second quarter worth $171,000. Northern Trust Corp boosted its holdings in shares of NeoGenomics by 2.2% during the second quarter. Northern Trust Corp now owns 998,807 shares of the medical research company’s stock worth $13,094,000 after purchasing an additional 21,293 shares during the last quarter. Finally, Strs Ohio boosted its holdings in shares of NeoGenomics by 13.2% during the third quarter. Strs Ohio now owns 300,000 shares of the medical research company’s stock worth $4,605,000 after purchasing an additional 35,000 shares during the last quarter. Hedge funds and other institutional investors own 82.57% of the company’s stock.

NASDAQ:NEO opened at $16.52 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.98 and a current ratio of 4.13. NeoGenomics, Inc. has a 12 month low of $7.08 and a 12 month high of $19.04. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of 275.00 and a beta of 0.43.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, October 30th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. NeoGenomics had a return on equity of 2.63% and a net margin of 1.70%. The company had revenue of $69.10 million for the quarter, compared to analyst estimates of $66.13 million. During the same period last year, the company posted $0.01 earnings per share. The firm’s revenue was up 16.8% compared to the same quarter last year. Equities research analysts anticipate that NeoGenomics, Inc. will post 0.11 EPS for the current fiscal year.

In other NeoGenomics news, VP Jennifer Balliet sold 68,333 shares of the firm’s stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $16.89, for a total value of $1,154,144.37. Following the transaction, the vice president now directly owns 55,000 shares of the company’s stock, valued at $928,950. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin C. Johnson acquired 26,000 shares of the business’s stock in a transaction on Friday, December 21st. The stock was bought at an average cost of $11.60 per share, for a total transaction of $301,600.00. Following the completion of the transaction, the director now directly owns 103,866 shares of the company’s stock, valued at $1,204,845.60. The disclosure for this purchase can be found here. Insiders sold 15,829,788 shares of company stock worth $213,793,738 over the last three months. 12.20% of the stock is currently owned by corporate insiders.

NEO has been the topic of several research reports. Benchmark set a $22.00 target price on NeoGenomics and gave the stock a “buy” rating in a research report on Thursday, November 1st. Craig Hallum increased their target price on NeoGenomics from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Raymond James increased their target price on NeoGenomics from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Zacks Investment Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a research report on Saturday, November 3rd. Finally, BidaskClub raised NeoGenomics from a “hold” rating to a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.33.

TRADEMARK VIOLATION NOTICE: This report was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/4115931/emerald-advisers-llc-has-24-07-million-holdings-in-neogenomics-inc-neo.html.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Heartland Express, Inc.  To Go Ex-Dividend on March 21st
Heartland Express, Inc. To Go Ex-Dividend on March 21st
Hays plc  Receives GBX 183.33 Average Target Price from Brokerages
Hays plc Receives GBX 183.33 Average Target Price from Brokerages
Magellan Midstream Partners, L.P.  Receives $69.77 Average PT from Brokerages
Magellan Midstream Partners, L.P. Receives $69.77 Average PT from Brokerages
Canoe EIT Income Fund  Plans $0.10 Monthly Dividend
Canoe EIT Income Fund Plans $0.10 Monthly Dividend
Upland Software  Reaches New 1-Year High at $42.69
Upland Software Reaches New 1-Year High at $42.69
Brokerages Set Tate & Lyle PLC  Price Target at $705.63
Brokerages Set Tate & Lyle PLC Price Target at $705.63


© 2006-2019 Ticker Report